Causes and evaluation of chronic dyspnea

American Family Physician

Volumn 86, Issue 2, 2012, Pages 173-180

  Wahls, Steven A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; BRONCHODILATING AGENT; D DIMER; DIURETIC AGENT; METHOTREXATE;

ARTICLE; BLOOD CELL COUNT; BRONCHOSCOPY; CHRONIC DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXPIRATORY FLOW; HEART CATHETERIZATION; HEART STRESS; HUMAN; INSPIRATORY CAPACITY; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG SCINTISCANNING; LUNG VENTILATION PERFUSION RATIO; QUESTIONNAIRE; RISK FACTOR; SPIROMETRY; THORAX RADIOGRAPHY;

EID: 84864656531     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Karnani NG, Reisfield GM, Wilson GR. Evaluation of chronic dyspnea. Am Fam Physician. 2005;71(8):1529-1537.
2. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med. 1999;159(1):321-340.
3. Shiber JR, Santana J. Dyspnea. Med Clin North Am. 2006;90(3):453-479.
4. Cottraux J. A clinical trap: acute and chronic psychogenic dyspnea [article in French]. Rev Pract. 2009;59(5):615-618.
5. Xu W, Collet JP, Shapiro S, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med. 2008;178(9):913-920.
6. American College of Radiology. ACR Appropriateness Criteria. Dyspnea-suspected cardiac origin. 2010. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/DyspneaSuspectedCardiacOrigin.pdf. Accessed July 12, 2012.
7. Sarkar S, Amelung PJ. Evaluation of the dyspneic patient in the office. Prim Care. 2006;33(3):643-657.
8. American College of Radiology. ACR Appropriateness Criteria. Chronic dyspnea-suspected pulmonary origin. 2012. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/ChronicDyspneaSuspectedPulmonaryOrigin.pdf. Accessed July 12, 2012.
9. Pratter MR, Curley FJ, Dubois J, Irwin RS. Cause and evaluation of chronic dyspnea in a pulmonary disease clinic. Arch Intern Med. 1989;149(10):2277-2282.
10. Stephens MB, Yew KS. Diagnosis of chronic obstructive pulmonary disease. Am Fam Physician. 2008;78(1):87-92.
11. Bolton CE, Ionescu AA, Edwards PH, Faulkner TA, Edwards SM, Shale DJ. Attaining a correct diagnosis of COPD in general practice. Respir Med. 2005;99(4):493-500.
12. Hanania NA, Mannino DM, Yawn BP, et al. Predicting risk of airflow obstruction in primary care: validation of the lung function questionnaire (LFQ). Respir Med. 2010;104(8):1160-1170.
13. U.S. National Library of Medicine. Hazardous Substances Data Bank. Amiodarone hydrochloride. http://toxnet.nlm.nih.gov/. Accessed November 23, 2010.
14. U.S. National Library of Medicine. Hazardous Substances Data Bank. Methotrexate. http://toxnet.nlm.nih.gov/. Accessed November 23, 2010.
15. Zoorob RJ, Campbell JS. Acute dyspnea in the office. Am Fam Physician. 2003;68(9):1803-1810.
16. McCullough PA, Hollander JE, Nowak RM, et al.; BNP Multinational Study Investigators. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003;10(3):198-204.
17. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006;100(12):2183-2189.
18. Holleman DR Jr, Simel DL. Does the clinical examination predict airflow limitation? [published correction appears in JAMA. 1995;273(17):1334]. JAMA. 1995;273(4):313-319.
19. Kalantri S, Joshi R, Lokhande T, et al. Accuracy and reliability of physical signs in the diagnosis of pleural effusion. Respir Med. 2007;101(3):431-438.
20. Currie GP, Legge JS. ABC of chronic obstructive pulmonary disease. Diagnosis. BMJ. 2006;332(7552):1261-1263.
21. Mogelvang R, Goetze JP, Schnohr P, et al. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol. 2007;50(17):1694-1701.
22. Straus SE, McAlister FA, Sackett DL, Deeks JJ. The accuracy of patient history, wheezing, and laryngeal measurements in diagnosing obstructive airway disease. CARE-COAD1 Group. Clinical Assessment of the Reliability of the Examination-Chronic Obstructive Airways Disease [published correction appears in JAMA. 2000;284(2):181]. JAMA. 2000;283(14):1853-1857.
23. Davenport C, Cheng EY, Kwok YT, et al. Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis. Br J Gen Pract. 2006;56(522):48-56.
24. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191.
25. Miller MR, Hankinson J, Brusasco V, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
26. Balion C, Santaguida PL, Hill S, et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evidence report/technology assessment no. 142. AHRQ publication no. 06-E014. Rockville, Md.: Agency for Healthcare Research and Quality; September 2006. http://www.ncbi.nlm.nih.gov/books/NBK38136/.December 29, 2011.
27. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomomized, controlled trial. J Am Coll Cardiol. 2003;42(10):1793-1800.
28. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009;113(13):2878-2887.
29. Martínez-García MA, Perpiñá-Tordera M, Soler-Cataluña JJ, Román-Sánchez P, Lloris-Bayo A, González-Molina A. Dissociation of lung function, dyspnea ratings and pulmonary extension in bronchiectasis. Respir Med. 2007;101(11):2248-2253.
30. Aneja A, Wilson Tang WH. Heart failure: role of cardiac imaging. In: Nicholls SJ, Worthley S, eds. Cardiovascular Imaging for Clinical Practice. Sudbury, Mass.: Jones and Bartlett; 2011:29-50.
31. Galiè N, Hoeper MM, Humbert M, et al.; Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34(6):1219-1263.
32. Tunariu N, Gibbs SJ, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48(5):680-684.
33. Balady GJ, Arena R, Sietsema K, et al.; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of Care and Outcomes Research. Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation. 2010;122(2):191-225.